Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we report the functional progress, side effects and survival...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Respir Dis
Main Authors: Vietri, Lucia, Cameli, Paolo, Perruzza, Marco, Cekorja, Behar, Bergantini, Laura, d’Alessandro, Miriana, Refini, Rosa Metella, Pieroni, Maria, Fossi, Antonella, Bennett, David, Spalletti, Marco, Mazzei, Maria Antonietta, Sestini, Piersante, Rottoli, Paola, Bargagli, Elena
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7029533/
https://ncbi.nlm.nih.gov/pubmed/32066332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620906326
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados